First Tracks Biotherapeutics Inc
NASDAQ:TRAXBiotechnology
-$0.89 today
- Market cap
- $1.87B
- Beta
- 0.00
- P/E (TTM)
- -6.1
- EPS (TTM)
- -$2.81
Volume 0.75M
Average 0.43M
TRAX Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
First Tracks Biotherapeutics IncNASDAQ: TRAX
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock remains negative
Q1 FY2026 common stock was $0, compared with $0 a year earlier.
Context
- Common stock amounted to 0.0% of total assets at the end of Q1 FY2026.
- Common stock increased in 0 of the last 2 fiscal years.
- FY2025 was the lowest annual figure in the 3 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 287.51M USD
- Year-over-year change
- -26.5%
- 2-year CAGR
- -16.3%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 287.51M | -26.5% |
| FY2024 | 2024-12-31 | 391.29M | -4.7% |
| FY2023 | 2023-12-31 | 410.65M | — |
Common Stock vs competitors
How TRAX compares with its peers on the latest reported figures
- TRAX's Mar 2026 common stock of $0 is the lowest of the 10 companies compared; the peer median is $8K.
- Common stock amounts to 0.0% of total assets for TRAX, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $76K | +26.7% | +75.0% | 0.1% | |
| Mar 2026 | $29K | -3.3% | -1.2% | 0.0% | |
| Sep 2026 | $20K | +17.6% | +15.4% | 0.0% | |
| Mar 2026 | $11K | +37.5% | +31.0% | 0.0% | |
| Jun 2026 | $8K | +754.7% | -2.2% | 0.0% | |
| Mar 2026 | $7K | +16.7% | +9.9% | 0.0% | |
CLYMClimb Bio, Inc. | Mar 2026 | $5K | -28.6% | +18.6% | 0.0% |
| Jun 2026 | $1K | — | — | 0.0% | |
| Mar 2026 | $1K | +0.0% | +0.0% | 0.0% | |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $0 | — | — | 0.0% |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding TRAX) | $8K | +17.2% | +12.7% | 0.0% | |
Competitors are the stored peer set for TRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
First Tracks Biotherapeutics Inc
NASDAQ:TRAX
Intrinsic Alpha fair value
Locked
Current Price
$44.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.